NO20072667L - Fremstillingsmetode - Google Patents

Fremstillingsmetode

Info

Publication number
NO20072667L
NO20072667L NO20072667A NO20072667A NO20072667L NO 20072667 L NO20072667 L NO 20072667L NO 20072667 A NO20072667 A NO 20072667A NO 20072667 A NO20072667 A NO 20072667A NO 20072667 L NO20072667 L NO 20072667L
Authority
NO
Norway
Prior art keywords
preparation process
compounds
preparation
her1
her4
Prior art date
Application number
NO20072667A
Other languages
English (en)
Inventor
Ashvinikumar Gavai
Ping Chen
Derek J Norris
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20072667L publication Critical patent/NO20072667L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for fremstilling av forbindelser med formel (IV) eller et farmasøytisk akseptabelt salt derav. Forbindelsene som er fremstilt ved fremgangsmåten ifølge oppfinnelsen, inhiberer tyrosinkinase-aktiviteten til vekstfaktor-reseptorer så som HER1, HER2 og HER4, og dette gjør dem anvendelige som antiproliferative midler for behandling av kreft og andre sykdommer.
NO20072667A 2004-12-22 2007-05-25 Fremstillingsmetode NO20072667L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63833504P 2004-12-22 2004-12-22
PCT/US2005/047630 WO2006069395A2 (en) 2004-12-22 2005-12-21 Synthetic process for the preparation of biocyclic compounds

Publications (1)

Publication Number Publication Date
NO20072667L true NO20072667L (no) 2007-09-06

Family

ID=36177994

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072667A NO20072667L (no) 2004-12-22 2007-05-25 Fremstillingsmetode

Country Status (9)

Country Link
US (1) US20060155125A1 (no)
EP (1) EP1896475A2 (no)
JP (1) JP2008525503A (no)
CN (1) CN101087792A (no)
AR (1) AR052276A1 (no)
NO (1) NO20072667L (no)
PE (1) PE20060951A1 (no)
TW (1) TW200635927A (no)
WO (1) WO2006069395A2 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006004976D1 (de) * 2005-03-28 2009-03-12 Bristol Myers Squibb Co Kompetitive atp-kinasehemmer
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
UY34484A (es) * 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
PL373371A1 (en) * 2002-04-23 2005-08-22 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
US7102001B2 (en) * 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US7064203B2 (en) * 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7102003B2 (en) * 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds

Also Published As

Publication number Publication date
JP2008525503A (ja) 2008-07-17
TW200635927A (en) 2006-10-16
EP1896475A2 (en) 2008-03-12
AR052276A1 (es) 2007-03-07
WO2006069395A3 (en) 2006-10-19
WO2006069395A2 (en) 2006-06-29
US20060155125A1 (en) 2006-07-13
PE20060951A1 (es) 2006-09-14
CN101087792A (zh) 2007-12-12

Similar Documents

Publication Publication Date Title
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
RS20050441A (en) C-6 modified indazolylpyrroltriazines
NO20061743L (no) Kinazolinderivater
MXPA04004492A (es) Indazolilpirrolotriazinas c-5 modificadas.
NO20072747L (no) Fremgangsmate for fremstilling av indazolforbindelser
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
DE602005023732D1 (de) Pyrrolotriazinverbindungen
NO20090581L (no) Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20090580L (no) Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
NO20070681L (no) 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
WO2005065266A8 (en) Di-substituted pyrrolotriazine compounds
NO20084496L (no) Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer
EA200801287A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
MXPA04004107A (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal.
NO20061415L (no) Kinazolinderivater
NO20062884L (no) AKT-proteinkinaseinhibitorer
NO20061327L (no) Kinazolinderivater
WO2009007751A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009155121A3 (en) Inhibitors of pi3 kinase
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
EP1973407A4 (en) SPIRO COMPOUNDS AND METHODS OF USE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application